Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AMD-3100 (AnorMED).

J P Vartanian1

  • 1Unité de Rétrovirologie Moléculaire, Bâtiment des Rétrovirus/SIDA, Institut Pasteur, 28 rue du Docteur Roux, 750015 Paris, France. jpvart@pasteur.fr

Idrugs : the Investigational Drugs Journal
|August 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulating pseudogene evolution in vitro: determining the true number of mutations in a lineage.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Polio vaccine samples not linked to AIDS.

Nature·2001
Same author

G --> A hypermutation does not result from polymerase chain reaction.

AIDS research and human retroviruses·1997
Same author

HIV genetic variation is directed and restricted by DNA precursor availability.

Journal of molecular biology·1997
Same author

Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions.

Nucleic acids research·1996
Same author

Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction.

Nucleic acids research·1995

AnorMED is developing AMD-3100, a CXCR4 antagonist, as a potential HIV treatment. This bis-tetraazamacrocycle inhibits HIV-1 and HIV-2 by interfering with viral uncoating and is in Phase II trials.

Area of Science:

  • Virology
  • Pharmacology
  • Drug Development

Background:

  • AnorMED is developing AMD-3100, a CXCR4 chemokine receptor antagonist.
  • AMD-3100 was discovered through a collaboration between AnorMED and the Rega Institute.
  • It is a potent inhibitor of HIV-1 and HIV-2 viruses.

Purpose of the Study:

  • To evaluate AMD-3100 as a potential treatment for HIV infection.
  • To assess the efficacy and safety of AMD-3100 in clinical trials.

Main Methods:

  • AMD-3100 is a bis-tetraazamacrocycle that interacts with the virus-associated uncoating process.
  • Phase II clinical trials are underway at The John's Hopkins University School of Medicine and two other US sites.
  • The Phase II trial involves 20 to 30 patients.

Related Experiment Videos

Main Results:

  • AMD-3100 is a potent inhibitor of HIV-1 and HIV-2.
  • The drug interacts with the virus-associated uncoating process.
  • Phase II trials are ongoing.

Conclusions:

  • AMD-3100 shows promise as a novel therapeutic agent for HIV infection.
  • Further clinical evaluation is necessary to confirm its efficacy and safety.
  • Market analysts predict a 2003 launch with significant sales potential.